At the heart of the Monash Learning Health System Maturity Matrix lies its fundamental intent: to provide a structured framework for healthcare organizations to evaluate their operational maturity within the broader context of a learning health system. As healthcare evolves, so too does the importance of effective evaluation mechanisms. The maturity matrix serves as a benchmark against which institutions can measure their capabilities in integrating data-driven practices into everyday healthcare delivery, thereby fostering an environment conducive to continuous improvement.

The collaborative design process of this matrix was marked by substantial input from a diverse array of stakeholders, including healthcare providers, policymakers, and patients. Engaging these groups in co-design not only ensures that the tool caters to real-world needs but also establishes a greater sense of ownership among users. Their insights draw attention to the multifaceted nature of healthcare systems, where behavior, culture, and policy interplay to influence outcomes.

The design of the Monash maturity matrix is informed by extensive literature on health systems, quality improvement methodologies, and theories of organizational change. By incorporating these diverse perspectives, the matrix encompasses various dimensions necessary for evaluating maturity, including leadership, technology use, data access, and interprofessional education. This holistic approach is critical, as it recognizes that successful transformation in health systems cannot occur in isolation but requires a comprehensive understanding of multiple interdependent factors.

Moreover, the matrix aims to transcend traditional evaluation frameworks by emphasizing the behavioral aspects of health systems. Recognizing that knowledge alone is insufficient for change, the tool encourages institutions to consider how their cultures and behaviors impact practices. This perspective fosters a more nuanced understanding of the challenges health organizations face and allows for tailored interventions that align with specific needs.

A key component in the application of the Monash LHS Maturity Matrix is its iterative nature, designed to evolve along with the health system itself. Users can repeatedly engage with the matrix, reassessing their positions and identifying areas ripe for improvement. This continuous feedback loop fosters a culture of learning, where insights and adjustments inform ongoing practice, enabling organizations to navigate the shifting landscapes of healthcare delivery effectively.

As the framework is put to test in real-world settings, the researchers are keen to gather data and feedback on its effectiveness. Initial pilot studies are anticipated to provide invaluable insights into how the matrix is utilized across various healthcare environments. These findings will not only refine the tool itself but also contribute to the broader discourse on learning health systems, ultimately bolstering evidence-based practices in healthcare.

The promise of the Monash Learning Health System Maturity Matrix extends beyond merely measuring current capabilities. It serves as a strategic guide for organizations aspiring to cultivate environments that support innovation and adaptability. By illuminating pathways for improvement, the tool empowers health systems to transition from reactive to proactive mindsets, whereby organizations continuously learn from their own practices and those of others.

Furthermore, its application could address real-time challenges faced during crises, as demonstrated during the COVID-19 pandemic. As health systems around the world grappled with the unprecedented demands placed upon them, tools like the maturity matrix could have provided frameworks to navigate rapid changes effectively and learn from those experiences to shape future responses and resilience strategies.

The collaborative nature of the research underscores the importance of interdisciplinary partnerships in shaping effective health system evaluation tools. The convergence of public health experts, data scientists, behavioral scientists, and clinicians enriches the matrix’s development and promotes cross-pollination of ideas. Such partnerships are essential for addressing the complexities of health systems, especially as they adapt to evolving societal needs and expectations.

While the matrix is an ambitious undertaking, it is grounded in the recognition that tools alone are not a panacea; they require a supportive ecosystem for implementation. Stakeholders across the healthcare spectrum must see the value in leveraging the insights derived from the tool, necessitating organizational commitment and an openness to change. This cultural shift is critical for fostering environments where learning and improvement are integral to daily operations.

In conclusion, the Monash Learning Health System Maturity Matrix represents a pivotal advancement in the way healthcare systems can understand and improve their operations. It embodies a comprehensive approach to evaluation that integrates behavioral insights and stakeholder engagement, paving the way for a future where health systems are not just high-functioning but also learning entities capable of adapting to ever-changing landscapes. The collective efforts from the research team and those involved in the co-design process lay a strong foundation that could redefine how healthcare organizations strive for excellence in patient care and operational efficiency.

As this matrix begins to make its mark within the healthcare community, it sparks important conversations about the nature of learning health systems and the substantial role they play in effecting meaningful change. The journey towards maturity in these complex systems is ongoing, and the Monash matrix could very well serve as a key navigational tool along the path to sustained improvement.

Subject of Research: The development and co-design of the Monash Learning Health System Maturity Matrix for measuring and guiding improvement in health systems.

Article Title: The Monash learning health system maturity matrix: codesign of a tool to measure and guide improvement in complex health system behaviour.

Article References:

Rajit, D., Johnson, A., Reeder, S. et al. The Monash learning health system maturity matrix: codesign of a tool to measure and guide improvement in complex health system behaviour. BMC Health Serv Res (2026). https://doi.org/10.1186/s12913-025-13923-y

Image Credits: AI Generated

DOI:

Keywords: Learning Health System, Maturity Matrix, Healthcare Improvement, Co-design, Health Systems Evaluation.

Dr. Kipum Lee brings a rich background of innovation leadership, strategic foresight, and operational expertise to his new presidency at UH Ventures. His academic credentials span prestigious institutions including the University of Pennsylvania, Carnegie Mellon University, and Case Western Reserve University, where he is also a faculty member at both the School of Medicine and the Weatherhead School of Management. This unique blend of academic rigor and practical industry experience equips Dr. Lee with the vision and skill set necessary to accelerate UH’s strategic goals.

Under his previous role as Vice President of Enterprise Strategy & Innovation, Dr. Lee spearheaded several transformative initiatives across the health system. These efforts have included the deployment of human-centered design methodologies within key clinical programs, such as the emergency departments, the UH Neurological Institute, and the Harrington Heart & Vascular Institute. This approach emphasizes empathic engagement of patients and healthcare providers, capturing nuanced insights to reengineer processes and service delivery for enhanced outcomes and efficiency.

Significantly, Dr. Lee co-designed and led innovation programs that provide early-stage capital to promising digital health and medtech concepts, as well as care redesign initiatives. By fostering early investment in emerging technologies and creative health solutions, UH Ventures under his guidance has become a vital incubator for ideas that address critical healthcare challenges and improve patient experience.

The launch and incubation of specialized centers such as the UH Cutler Center for Men, RadiCLE, and the Veale Healthcare Transformation Institute further underscore the breadth of Dr. Lee’s impact. These entities serve as hubs for research, technology development, and clinical innovation, facilitating interdisciplinary collaboration that pushes the frontiers of medical science and healthcare delivery within and beyond the UH network.

Dr. Lee’s vision for UH Ventures aligns with building sustainable business opportunities that complement University Hospitals’ broader enterprise strategy. This entails driving revenue growth, enhancing operational margins, and systematically deploying resources into high-potential technologies with scalable impact. His leadership is focused on institutionalizing innovation practices, ensuring that entrepreneurial thinking permeates every level of the organization and is embedded into its core culture.

Beyond the confines of University Hospitals, Dr. Lee’s career reflects a strong dedication to advancing health innovation on a global scale. Notably, he contributed to a mobile health initiative in South Africa that garnered international recognition by The Economist, highlighting his capacity to create impactful, technology-driven healthcare solutions responsive to diverse settings. Moreover, his involvement in developing the Marriott Mobile platform exemplifies his proficiency in leveraging mobile technology to enhance user engagement and commercial success.

David Sylvan, MBA, who previously led UH Ventures and remains Chief Strategy, Innovation & Marketing Officer for University Hospitals, emphasized the significance of Dr. Lee’s leadership. Sylvan praised the “culture of innovation” cultivated under Dr. Lee’s stewardship and the team’s proficiency in design thinking that informs a wide array of healthcare innovations—from process redesign and product development to patient engagement frameworks. This institutional foundation positions UH Ventures as a vital accelerator of entrepreneurial success and systemic transformation.

Strategic collaboration also forms a cornerstone of Dr. Lee’s leadership philosophy. Among his notable partnerships are initiatives with the NASA Glenn Research Center and Eaton Corporation, as well as active participation in the Cleveland Innovation District. These alliances foster cross-sector innovation, enabling UH to integrate advanced technologies and business models from aerospace, manufacturing, and other industries into healthcare solutions.

In his new capacity as President of UH Ventures, Dr. Lee is poised to not only sustain but amplify the health system’s momentum in innovation. His approach emphasizes hands-on leadership to integrate strategic enterprise objectives with the tactical support required by innovators and entrepreneurs. This dual focus ensures that promising ideas can transition seamlessly from conception through development to scalable deployment.

Dr. Lee’s editorial role with MIT Press’s Design Issues highlights his engagement with scholarly discourse on design and innovation theory, which informs practical applications at UH. His contributions extend beyond UH through board memberships, including active participation in Northeast Ohio’s entrepreneurial ecosystem via organizations like JumpStart, Inc. This multifaceted involvement demonstrates his commitment to fostering innovation ecosystems both within the health system and the broader community.

The promotion of Dr. Lee as President signals a strengthened intent by University Hospitals to harness innovation as a strategic asset essential to sustaining clinical excellence, economic growth, and improved health outcomes. As healthcare continues to face unprecedented challenges amid technological advancement and demographic change, UH Ventures represents an engine for creative disruption and value creation under Dr. Lee’s visionary leadership.

Founded in 1866, University Hospitals has evolved into a comprehensive healthcare network encompassing more than 20 hospitals and numerous outpatient facilities across northern Ohio. Its flagship academic medical center, affiliated with Case Western Reserve University, stands at the forefront of clinical research and patient care innovation, consistently ranked among the nation’s best. The integration of advanced clinical programs, academic excellence, and a robust culture of innovation positions University Hospitals to continue setting new standards in healthcare delivery.

As UH Ventures charts its future trajectory, Dr. Kipum Lee’s appointment heralds an era where technological innovation, entrepreneurial funding, and strategic collaboration converge to revolutionize healthcare services. This leadership transition represents more than an administrative change—it reflects a deliberate and sustained commitment by University Hospitals to redefine how care is conceived, delivered, and evolved in a complex, interconnected world.

Subject of Research:
Article Title:
News Publication Date: October 1, 2023
Web References: https://ventures.uhhospitals.org/team/kipum-lee/; https://www.uhhospitals.org/about-uh/leadership/uh-system-leadership/david-sylvan
Image Credits: University Hospitals
Keywords: Health care industry, Entrepreneurship, Corporations, Medical economics, Health care

At its core, the MVP program is a strategic platform that leverages the extensive clinical and research capabilities of Mayo Clinic with the operational and financial acumen of its venture partners. The partners are tasked with identifying promising innovations derived from Mayo Clinic’s collaborative endeavors, guiding the formation of novel enterprises, and deploying capital into companies with the potential to catalyze meaningful improvements in patient care. This melding of intellectual capital and entrepreneurial vigor is designed not only to streamline commercialization but to foster an environment where innovative technologies can flourish from conception to implementation with greater speed and efficiency.

The inaugural cohort of Mayo Venture Partners heralds a triad of leadership with diverse yet complementary backgrounds. Amy DuRoss brings to the table profound expertise across healthcare innovation, policy formulation, and diagnostic commercialization, skills essential for navigating the complexities of healthcare markets and regulatory frameworks. Audrey Greenberg contributes extensive experience in launching and scaling ventures across the life sciences and healthcare sectors, positioning her as a formidable force in company-building and operational strategy. Finally, Brian Poger, a serial entrepreneur with a notable track record in digital health and healthcare services, rounds out the group with his insight into disruptive technologies and healthcare delivery models. Together, these leaders form an executive constellation poised to amplify Mayo Clinic’s influence on the healthcare innovation frontier.

Historically, Mayo Clinic’s Business Development team has been instrumental in driving economic impact and intellectual property advancement within the institution. With an impressive portfolio that surpasses $1.2 billion in revenue returned to support clinical practice, education, and research, the team’s contributions extend far beyond mere financial metrics. The creation of over 180 companies from Mayo Clinic innovations, coupled with more than 4,800 licensed technologies under nearly 3,000 agreements and the issuance of more than 4,100 patents, underscores an ecosystem deeply embedded in fostering novel ideas and translating them into scalable products and services that benefit patients worldwide.

The MVP program exemplifies Mayo Clinic’s strategic pivot towards models that emphasize active collaboration and co-investment with external partners. Recognizing that no single institution can singularly navigate the complexities intrinsic to modern healthcare innovation, Mayo Clinic is cultivating a network that integrates domain expertise, market insights, and capital resources. This approach facilitates not just incremental evolution but transformative breakthroughs—cutting-edge therapeutics, advanced diagnostics, and technology-enabled care delivery systems—that collectively redefine standards of care and patient experience.

Patient-centric innovation remains the fulcrum of the program’s mission. By accelerating the development of technologies that expand access, reduce costs, and improve clinical outcomes, the MVP initiative aligns uncompromising scientific rigor with practical healthcare delivery imperatives. It seeks to address pervasive challenges such as health disparities, fragmented care coordination, and chronic disease management through inventions that empower both providers and patients. The portfolio of ventures emerging from this program is expected to span a broad spectrum, from molecular diagnostics and personalized medicine to artificial intelligence-driven decision support systems and telehealth platforms.

Another critical dimension of the MVP model is its emphasis on agility and responsiveness within a shifting regulatory environment. As government agencies evolve oversight frameworks to keep pace with rapid innovation, the program’s leaders are uniquely equipped to navigate these domains, ensuring that emerging products not only meet stringent safety and efficacy criteria but also expedite their path to market. This competency reduces time-to-impact for new technologies and bolsters investor confidence, creating a virtuous cycle of innovation and adoption.

The launch of the MVP program is also a testament to Mayo Clinic’s recognition of the importance of strategic partnerships that transcend academic boundaries. By engaging with industry veterans who have both operational experience and investment expertise, the initiative opens channels to resources, networks, and competencies that are often inaccessible within traditional research settings. This broader engagement supports the systemic integration of innovations into healthcare infrastructure, facilitating broader dissemination and sustainable impact.

Integral to the MVP program is its alignment with Mayo Clinic’s overarching vision of transforming healthcare through integrative innovation. The initiative supports the translation of complex datasets, sophisticated bioinformatics, and emergent technologies into viable solutions capable of addressing unmet clinical needs. By fostering a pipeline for innovation that extends from discovery to commercial deployment, Mayo Clinic seeks to maintain its leadership role in shaping a future healthcare paradigm that is more precise, accessible, and equitable.

Furthermore, the program underscores the critical importance of intellectual property management and commercialization expertise. Mayo Clinic’s Business Development team, collaborating closely with MVP members, provides the scaffolding necessary to navigate the patent landscape, licensing negotiations, and startup incubation. This support maximizes the value of inventions, ensuring that promising innovations do not stagnate but instead mature into products that can transform clinical practice.

Inclusion within the MVP initiative also carries significant implications for external stakeholders including investors, executives, and innovation leaders worldwide. The program’s structure invites collaboration on projects that have been rigorously vetted for scientific merit and aligned with pressing healthcare challenges. This appeal enhances cross-sector connectivity, uniting visionaries committed to patient-centric paradigms and driving systemic improvements.

As health systems globally grapple with escalating costs and the demand for improved outcomes, Mayo Clinic’s MVP program serves as a blueprint for harnessing academic research’s potential while fostering entrepreneurial dynamism. By enabling direct engagement between researchers and business professionals, it catalyzes the maturation of ideas into actionable healthcare innovations that address real-world needs, ultimately improving patient quality of life at scale.

Those interested in learning more about Mayo Clinic’s Business Development or engaging with the MVP program are encouraged to visit the official website, subscribe to the e-newsletter, and follow Mayo Clinic Ventures on LinkedIn. These resources provide updates on ongoing projects, investment opportunities, and the latest strategic initiatives born from the intersection of medical science and venture development.

Subject of Research: Healthcare Innovation and Commercialization at Mayo Clinic
Article Title: Mayo Clinic Launches Mayo Venture Partner Program to Accelerate Healthcare Innovation
News Publication Date: Not specified
Web References:

• https://businessdevelopment.mayoclinic.org/
• https://links.e.response.mayoclinic.org/busdev
• https://www.linkedin.com/showcase/mayo-clinic-ventures/
• https://www.mayoclinic.org/about-mayo-clinic?mc_id=us&utm_source=newsnetwork&utm_medium=l&utm_content=content&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&invsrc=other&cauid=100721
• https://newsnetwork.mayoclinic.org/
  Keywords: Entrepreneurship, Business, Healthcare Innovation, Venture Capital, Digital Health, Diagnostics, Life Sciences

Esser’s extensive background in developing medical therapies, especially in the biopharmaceutical sector, equips him with the expertise necessary to lead this initiative effectively. His leadership will focus on creating an ecosystem that encourages collaboration among researchers, clinicians, and industry partners. This collaborative environment will not only foster innovation but also attract biotechnology companies to Central Virginia. The resulting influx of biotechnological expertise and resources is expected to generate hundreds of direct jobs and potentially thousands of indirect employment opportunities.

The establishment of the Manning Institute reflects a remarkable financial backing, totalling an impressive $350 million. This includes a $100 million donation from philanthropists Paul and Diane Manning, supplemented by an equal amount from the Commonwealth of Virginia and a further $150 million from UVA itself. Such financial commitment underscores confidence in the institute’s capacity to revolutionize both local healthcare and the economy of Virginia. The ambitious plans for the institute seek to advance the state of health sciences while securing Virginia’s position as a leader in biomedicine.

Mark Esser brings a wealth of knowledge to his new role, having previously served as a vice president at AstraZeneca, where he directed research and development across a variety of vaccine and immune therapeutic programs. His contributions at AstraZeneca have included oversight of projects that have drastically moved from concept to regulatory approval, illustrating his capability to navigate complex medical research landscapes. Esser’s appointment thus signifies a culmination of experience that bridges cutting-edge medical research with practical applications in clinical settings, significantly enhancing his ability to lead the Manning Institute.

The Manning Institute is envisaged to span 350,000 square feet, featuring advanced research facilities and manufacturing capabilities under one roof. It aims to integrate high-tech research practices with patient care, ensuring that discoveries made within the research realm quickly transition into clinical applications. This model of innovation is imperative in light of contemporary healthcare challenges, where the speed of research translation often determines outcomes. By facilitating rapid access to new treatments, the institute aspires to improve healthcare delivery for patients across Virginia and beyond.

UVA President James E. Ryan praised Esser’s appointment, highlighting his scientific acumen and ability to foster collaborative environments. He emphasized that Esser has the necessary skills to build bridges between academia and industry, which is crucial in today’s fast-evolving biomedical landscape. By harnessing the collaborative power of various stakeholders, Esser is expected to lead the charge in transforming scientific breakthroughs into tangible medical advancements, shaping the future of health care for generations to come.

As the Manning Institute gears up for its official operational launch, Esser’s vision includes creating pathways for improved patient access to clinical trials. The development of a statewide clinical trials network will allow for expanded participation in groundbreaking research efforts, facilitating real-time patient access to the latest treatments and therapies. This initiative is particularly vital as the healthcare system grapples with evolving diseases and the demand for new therapeutics continues to rise.

Esser’s return to UVA is a homecoming of sorts; he earned his PhD in microbiology from the UVA School of Medicine in 1998. His profound understanding of the intricacies of medical research allows him to propose innovative solutions while maintaining a systematic approach to the challenges faced in the industry. As he steps into his leadership role, he expresses enthusiasm for the unique opportunity this position presents, indicating a firm commitment to advancing both the University’s and the Institute’s mission.

The potential impact of the Manning Institute extends beyond immediate healthcare solutions; it is anticipated to serve as an economic driver for the region. By attracting biotech firms and research-driven enterprises to central Virginia, the Institute will contribute significantly to local job creation and economic vitality. This fusion of academic research and commercial interests is pivotal, as it positions UVA as a central player in an increasingly competitive global biotech environment.

Esser’s scientific expertise spans multiple critical domains, including immunology, virology, and diagnostics. His comprehensive background provides a robust foundation for spearheading the Institute’s initiatives. Notably, he has accumulated significant leadership experience in managing substantial budgets and directing large teams of researchers—capabilities that will be crucial as he undertakes the task of optimizing research funding and expanding organizational impact.

The design of the Manning Institute fosters a culture of interdisciplinary collaboration, emphasizing the need for diverse skill sets in problem-solving within medical research. The cross-pollination of ideas amongst various scientific disciplines will be instrumental in uncovering innovative therapies and advancing the delivery of healthcare solutions. Esser’s leadership philosophy is grounded in the belief that collaborative teamwork can generate results far surpassing those achieved by individual efforts alone.

As the institute begins shaping its identity, fostering relationships with global stakeholders will be essential. The Institute’s strategic vision will involve creating partnerships that transcend geographical and disciplinary boundaries to enhance research and clinical outcomes. Such partnerships will enable the sharing of data, technology, and expertise, further accelerating the development of medical advancements that can reach the patient bedside more swiftly.

Ultimately, with an unwavering commitment to transforming healthcare and enhancing patient outcomes, the Manning Institute’s establishment under Mark T. Esser’s leadership marks a new chapter in the University of Virginia’s pursuit of excellence in medical research. It embodies the promise of innovation, collaboration, and a relentless drive to improve human health, ultimately paving the way toward breakthrough discoveries that could reshape the very landscape of modern medicine. As we look to the horizon, the good that may emerge from the Manning Institute echoes the potential for a healthier future, one where the synergy of knowledge and industry can lead to life-saving treatments and thriving communities.

Subject of Research: Biomedical Research and Biotechnology
Article Title: Mark T. Esser Named Inaugural Head of UVA’s Manning Institute
News Publication Date: October 23, 2023
Web References: University of Virginia News
References: None
Image Credits: Courtesy Mark T. Esser

Keywords: Biotechnology, Medical Research, UVA, Paul and Diane Manning Institute, Health Innovation, Esser, Biopharmaceuticals, Clinical Trials, Patient Care, Economic Impact